Salih Aksu

1. Therapeutic Plasma Exchange Procedures and Outcomes in a Pediatric Intensive Care Unit: A Single-center ExperienceAksoy E. A., Kesici S., Unal S., AKSU S., BAYRAKCI B.JAREM, cilt.16, sa.2, ss.106-112, 2026 (ESCI, TRDizin)
2. Investigation of kinesiophobia, physical activity, quality of life, depression and anxiety level in adult people with hemophilia: A frequency-matched case-control studyOnal Aykar S., CAN F., AKSU S., Sahin F.Journal of Back and Musculoskeletal Rehabilitation, 2026 (SCI-Expanded, Scopus)
3. Comparison of pain catastrophizing, kinesiophobia, adaptation to artificial joint and functional outcomes following total knee arthroplasty in hemophiliaKINIKLI G. İ., KANLIKAYA U. G., GÖKER B., ÇAĞLAR Ö., TOKGÖZOĞLU A. M., ATİLLA B., et al.JOURNAL OF HEALTH SCIENCES AND MEDICINE, 2025 (TRDizin)
4. Retrospective analysis of hemophilia B in Turkey: identifying main characteristics and treatment optionsZulfikar B., Koc B., Sahin F., Sasmaz H. I., Kavakli K., Balkan C., et al.RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, cilt.8, sa.7, 2024 (SCI-Expanded, Scopus)
5. Postoperative bleeding adversely affects total knee arthroplasty outcomes in hemophiliaGöker B., Çağlar Ö., Kınıklı G. İ., Aksu S., Tokgözoğlu A. M., Atilla B.Knee, cilt.39, ss.261-268, 2022 (SCI-Expanded, Scopus)
6. Extracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA)Kaynar L., Tekgunduz E., KOZANOĞLU İ., Ozkan H. A., AKSU S., ÖZKALEMKAŞ F., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.61, sa.1, 2022 (SCI-Expanded, Scopus)
7. Comprehensive Assessment of Common Medical Problems in Adult Patients with Hemophilia A: A Single-Center Experience in TurkeyAydin M. S., Ciftciler R., İNKAYA A. Ç., AKSU S.GAZI MEDICAL JOURNAL, cilt.33, sa.1, ss.1-4, 2022 (ESCI, Scopus)
8. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantationKARATAŞ A., GÖKER H., DEMİROĞLU H., MALKAN Ü. Y., Velet M., ÇINAR O. E., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.2, ss.413-419, 2022 (SCI-Expanded, Scopus, TRDizin)
9. Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 VaccineErdogdu B., ÇINAR O. E., Malkan Ü. Y., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.32, sa.1, ss.65-67, 2022 (SCI-Expanded, Scopus, TRDizin)
10. Sarcopenia and anthracycline cardiotoxicity in patients with cancerBAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded, Scopus)
11. Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experienceGoren Sahin D., Akay O. M., KEKLİK M., Okan V., KARAKUŞ A., Demir C., et al.ANNALS OF HEMATOLOGY, cilt.100, ss.1667-1675, 2021 (SCI-Expanded, Scopus)
12. Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemiaALADAĞ KARAKULAK E., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.60, sa.2, 2021 (SCI-Expanded, Scopus)
13. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase InhibitorsKARAKULAK U. N., ALADAĞ KARAKULAK E., HEKİMSOY V., ŞAHİNER M. L., KAYA E. B., ÖZER N., et al.CARDIOVASCULAR TOXICOLOGY, cilt.21, sa.3, ss.216-223, 2021 (SCI-Expanded, Scopus)
14. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Munster Chemotherapy in Adult Acute Lymphoblastic LeukemiaALADAĞ KARAKULAK E., Aktimur S. H., Aydin O., DEMİROĞLU H., BÜYÜKAŞIK Y., AKSU S., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.3, ss.147-153, 2021 (SCI-Expanded, Scopus)
15. Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in turkey: a multicenter retrospective analysisKEKLİK KARADAĞ F., Yenerel M. N., YILMAZ M., ÜSKÜDAR TEKE H., ÖZKOCAMAN V., Tuglular T. F., et al.AMERICAN JOURNAL OF BLOOD RESEARCH, cilt.11, sa.3, ss.279-285, 2021 (ESCI)
16. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell TransplantationCiftciler R., GÖKER H., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.38, sa.1, ss.33-40, 2021 (SCI-Expanded, Scopus, TRDizin)
17. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasmaKARATAŞ A., İNKAYA A. Ç., DEMİROĞLU H., AKSU S., Haziyev T., ÇINAR O. E., et al.Transfusion and Apheresis Science, cilt.59, sa.5, 2020 (SCI-Expanded, Scopus)
18. Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor Case report and review of the literatureŞAHİN T. K., ALADAĞ KARAKULAK E., Setterzade E., SAİN GÜVEN G., HAZNEDAROĞLU İ. C., AKSU S.MEDICINE, cilt.99, sa.26, 2020 (SCI-Expanded, Scopus)
19. Cardiac adverse events during stem cell transplantation for hematological malignancies: A single centre experienceALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., KARAKULAK U. N., Tekin F., AKSU S., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.59, sa.2, 2020 (SCI-Expanded, Scopus)
20. FUNCTIONAL STATUS AND FEAR OF MOVEMENT LEVELS OF HEMOPHILIA A PATIENTS FOLLOWING TOTAL KNEE ARTHROPLASTYBOZGEYİK S., KINIKLI G. İ., AKSU S., ATİLLA B., Guney-Deniz H.HAEMOPHILIA, cilt.26, ss.171, 2020 (SCI-Expanded, Scopus)
21. Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantationCiftciler R., GÖKER H., BÜYÜKAŞIK Y., KARAAĞAÇ AKYOL T., AKSU S., Tekin F., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.59, sa.1, 2020 (SCI-Expanded, Scopus)
22. The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid LeukemiaCiftciler R., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., AKSU S., DEMİROĞLU H., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.2, ss.116-120, 2020 (SCI-Expanded, Scopus, TRDizin)
23. Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patientsCiftciler R., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., et al.HEMATOLOGY REPORTS, cilt.12, sa.1, 2020 (ESCI, Scopus)
24. Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at DiagnosisCiftciler R., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.4, ss.256-262, 2020 (SCI-Expanded, Scopus, TRDizin)
25. The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapyCiftciler R., HAZNEDAROĞLU İ. C., Ozcebe O., AKSU S., SAYINALP N., GÖKER H., et al.IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, cilt.42, sa.1, ss.17-21, 2020 (SCI-Expanded, Scopus)
26. Effects of Smoking on Hematological Parameters and Ferritin LevelsCiftciler R., Guven A., HAZNEDAROĞLU İ. C., AKSU S.HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, cilt.57, sa.4, ss.372-376, 2019 (ESCI, Scopus, TRDizin)
27. SECONDARY MALIGNANCIES IN PATIENTS WITH MULTIPLE MYELOMAALADAĞ KARAKULAK E., BÜYÜKAŞIK Y., DEMİROĞLU H., AKSU S., GÖKER H.AMERICAN JOURNAL OF HEMATOLOGY, cilt.94, 2019 (SCI-Expanded, Scopus)
28. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid LeukemiaCiftciler R., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., Ozcebe O., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.11, ss.729-734, 2019 (SCI-Expanded, Scopus)
29. CYTOGENETIC ANOMALIES IN MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER STUDYBOZKURT S., BÜYÜKAŞIK Y., DEMİROĞLU H., ALADAĞ KARAKULAK E., OKAY M., KARATAŞ A., et al.Genetics and Application, cilt.3, sa.1, ss.51-56, 2019 (Hakemli Dergi)
30. The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemiaGhasemi M., OKAY M., TÜRK S., Naeemaee R., Guver E., Malkan Ü. Y., et al.JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, cilt.20, sa.2, 2019 (SCI-Expanded, Scopus)
31. Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid LeukemiaCiftciler R., DEMİROĞLU H., BÜYÜKAŞIK Y., AKSU S., Gokei H.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.5, 2019 (SCI-Expanded, Scopus)
32. The Impact of AT1R Inhibition via Losartan on the Anti-Leukemic Effects of Doxorubicin in Acute Myeloid Leukemia.GHASEMİ m., OKAY M., TÜRK S., HAZNEDAROĞLU İ. C., AKSU S., SAYINALP N., et al.Journal Of The Renin-Angiotensin-Aldosterone System, 2019 (SCI-Expanded, Scopus)
33. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid LeukemiaCiftciler R., DEMİROĞLU H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.3, ss.177-182, 2019 (SCI-Expanded, Scopus)
34. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphomaOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., Malkan Ü. Y., Ciftciler R., ALADAĞ KARAKULAK E., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.4, ss.985-992, 2019 (SCI-Expanded, Scopus, TRDizin)
35. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort StudyCiftciler R., GÖKER H., DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.36, sa.2, ss.88-96, 2019 (SCI-Expanded, Scopus, TRDizin)
36. The factors affecting early death in newly diagnosed APL patientsCiftciler R., HAZNEDAROĞLU İ. C., AKSU S., Ozcebe O., SAYINALP N., Malkan Ü. Y., et al.OPEN MEDICINE, cilt.14, sa.1, ss.647-652, 2019 (SCI-Expanded, Scopus)
37. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiencyALADAĞ KARAKULAK E., AKSU S., DEMİROĞLU H., SAYINALP N., GÖKER H., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.5, ss.1560-1563, 2019 (SCI-Expanded, Scopus, TRDizin)
38. The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseasesTurk C., OKAY M., TÜRK S., Temirci E. S., Javad O., AKSU S., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.2, ss.661-674, 2019 (SCI-Expanded, Scopus, TRDizin)
39. Fibrosis Development, Leukemic Transformation and Secondary Malignancies Complicating the Clinical Course of Essential ThrombocythemiaCiftciler R., AKSU S., Malkan Ü. Y., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.29, sa.1, ss.14-21, 2019 (SCI-Expanded, Scopus, TRDizin)
40. Indications and outcomes of splenectomy for hematological disordersCiftciler R., Pasayeva A., AKSU S., Ozcebe O., SAYINALP N., Malkan Ü. Y., et al.OPEN MEDICINE, cilt.14, sa.1, ss.491-496, 2019 (SCI-Expanded, Scopus)
41. Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological studyCiftciler R., AKSU S., Dikmenoglu Falkmarken N., Celalettin Haznedaroglu I.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.1, ss.356-360, 2019 (SCI-Expanded, Scopus, TRDizin)
42. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patientsCIFTCILER R., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., AKSU S., Sayinalp N., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.57, sa.6, ss.752-755, 2018 (SCI-Expanded, Scopus)
43. Combination of novoseven and feiba in hemophiliac patients with inhibitorsMalkan Ü. Y., AKSU S.OPEN MEDICINE, cilt.13, sa.1, ss.618-621, 2018 (SCI-Expanded, Scopus)
44. Pediatric Chemotherapeutic Regimen (BFM-95) is Superior for Overall Survival in Adult Acute Lymphoblastic LeukemiaKARCIOĞLU A. M., OKAY M., BÜYÜKAŞIK Y., Malkan Ü. Y., SAYINALP N., DEMİROĞLU H., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.28, sa.4, ss.254-260, 2018 (SCI-Expanded, Scopus, TRDizin)
45. The impact of chemo/immune therapy-related cytopenias on the clinical course of chronic lymphoid leukemiaMalkan Ü. Y., OKAY M., HAZNEDAROĞLU İ. C., GÜNEŞ G., Aslan N. A., ÖZCEBE O. İ., et al.LEUKEMIA & LYMPHOMA, cilt.58, ss.96, 2017 (SCI-Expanded)
46. Bell s palsy as an early manifestation of acute lymphoblastic leukemiaÖZÇAKAR L., AKINCI TAN F. A., ÖZGÖÇMEN S., AKSU S., ERG Ç.Annals Of Hematology, 2017 (SCI-Expanded, Scopus)
47. Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell linesTÜRK TÜRK S., Malkan Ü. Y., Ghasemi M., Hocaoglu H., Mutlu D., Gunes G., et al.SAGE OPEN MEDICINE, cilt.5, 2017 (ESCI, Scopus)
48. Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in RemissionAYDIN M. S., BOZKURT S., GÜNEŞ G., Malkan Ü. Y., Aslan T., ETGÜL S., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.34, sa.1, ss.103-104, 2017 (SCI-Expanded, Scopus, TRDizin)
49. The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical PracticeMalkan Ü. Y., GÜNEŞ G., GÖKER H., HAZNEDAROĞLU İ. C., Acar K., ELİAÇIK E., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.33, sa.4, ss.281-285, 2016 (SCI-Expanded, Scopus, TRDizin)
50. Comparison of Myelodysplastic Syndrome Prognostic Scoring SystemsBEKTAŞ Ö., ÜNER A., ELİAÇIK E., Uz B., Isik A., ETGÜL S., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.33, sa.2, ss.119-126, 2016 (SCI-Expanded, Scopus, TRDizin)
51. The Impact of Iron Overload on Transplant-Related Complications and Prognosis of Acute LeukemiasMalkan U. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., Yayar O., ETGÜL S., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.26, sa.1, ss.54-60, 2016 (SCI-Expanded, Scopus, TRDizin)
52. The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative DiseasesAktimur S. H., Malkan U. Y., Eyupoglu D. N., HAZNEDAROĞLU İ. C., KELKİTLİ E., Atay H. M., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.26, sa.3, ss.153-158, 2016 (SCI-Expanded, Scopus, TRDizin)
53. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple MyelomaGHASEMİ m., ALPSOY S., TÜRK TÜRK S., MALKAN Ü. Y., ATAKAN Ş., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.33, sa.4, ss.286-292, 2016 (SCI-Expanded, Scopus, TRDizin)
54. Idelalisib at the Crossroads of B-Cell Lymphoproliferative DisordersAKSU S., Ayyildiz O., ETGÜL S., GÖKER H., GÜNEŞ G., HAZNEDAROĞLU İ. C., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.26, sa.1, ss.12-19, 2016 (SCI-Expanded, Scopus, TRDizin)
55. Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemiaELİAÇIK E., Isik A., Aydin C., ÜNER A., AKSU S., SAYINALP N., et al.HEMATOLOGY, cilt.20, sa.7, ss.392-396, 2015 (SCI-Expanded, Scopus)
56. High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiologyBEKTAŞ Ö., ÜNER A., Aydin S. M., ELİAÇIK E., Uz B., Isik A., et al.INTERNATIONAL JOURNAL OF HEMATOLOGY, cilt.102, sa.2, ss.211-217, 2015 (SCI-Expanded, Scopus)
57. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative NeoplasmsELİAÇIK E., Isik A., AKSU S., ÜNER A., BÜYÜKAŞIK Y., SAYINALP N., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.32, sa.2, ss.163-167, 2015 (SCI-Expanded, Scopus, TRDizin)
58. Clinicopathological associations of acquired erythroblastopeniaGÜNEŞ G., Malkan Ü. Y., YAŞAR H. A., ELİAÇIK E., HAZNEDAROĞLU İ. C., DEMİROĞLU H., et al.INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, cilt.8, sa.12, ss.22515-22519, 2015 (SCI-Expanded, Scopus)
59. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CMLMalkan U. Y., AKSU S., Aktimur S. H., Atay H., Bektas O., BÜYÜKAŞIK Y., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.25, sa.4, ss.215-221, 2015 (SCI-Expanded, Scopus, TRDizin)
60. The factors affecting early death after the initial therapy of acute myeloid leukemiaMalkan Ü. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., ETGÜL S., Aslan T., et al.INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, cilt.8, sa.12, ss.22564-22569, 2015 (SCI-Expanded, Scopus)

All 113 on AVESİS →

1. EŞLEŞTİRİLMİŞ KOHORT ÇALIŞMASI: HEMOFİLİ HASTALARINDA TOTAL DİZ ARTROPLASTİSİ SONRASI AĞRI KATASTROFİZASYONU, KİNEZYOFOBİ, YAPAY EKLEM UYUMU VE FONKSİYONEL SONUÇLARKANLIKAYA U. G., GÖKER B., ATİLLA B., TOKGÖZOĞLU A. M., ÇAĞLAR Ö., KINIKLI G. İ., et al.“33. Ulusal Türk Ortopedi ve Travmatoloji Kongresi”, Antalya, Türkiye, 29 Eylül 2024, (Özet Bildiri)
2. Demir Eksikliği Anemisi Tanısı Alan HastalarınTedavi Öncesi ve Sonrası Yaşam Kalitesinin DeğerlendirilmesiBEŞE T., AYHAN BAŞER D., AKSU S.Ulusal Aile Hekimliği Kongresi 2020 (19. Ulusal Aile Hekimliği Kongresi), Online, Türkiye, 29 Ekim - 01 Kasım 2020, (Özet Bildiri)
3. FUNCTIONAL STATUS AND FEAR OF MOVEMENT LEVELS OF HEMOPHILIA A PATIENTS FOLLOWING TOTAL KNEE ARTHROPLASTYBOZGEYİK S., KINIKLI G. İ., AKSU S., ATİLLA B., GÜNEY DENİZ H.EAHAD2020/NETHERLANDS, The Hague, Hollanda, 5 - 07 Şubat 2020, (Özet Bildiri)
4. THE EVALUATION OF THE CLINICOPATHOLOGIC CHARACTERISTICS OF T-CELL NON-HODGKIN’S LYMPHOMA: THE SINGLE CENTER EXPERIENCESAYINALP N., ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., AKSU S., DEMİROĞLU H., et al.15th International Conference on Malignant Lymphoma, İsviçre, 18 - 22 Haziran 2019, cilt.37, ss.366, (Özet Bildiri)
5. ASEMPTOMATİK D-DİMER YÜKSEKLİĞİ İMMÜNMONULATUAR KULLANAN MULTİPLE MYELOMADA TROMBOZU TAHMİN EDER Mİ: GERÇEK YAŞAM VERİSİAYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., YAZGAN S. Ç., DEMİROĞLU H., ÖZCEBE O. İ., et al.4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)
6. ALLOJENİK KÖK HÜCRE NAKLİ SONRASI RELAPS İZLENEN AKUT LÖSEMİ HASTALARINDA TEDAVİ SEÇENEKLERİ: DONÖR LENFOSİT İNFUZYONU VE İKİNCİ ALLOJENİK KÖK HÜCRE NAKLİNİN KARŞILAŞTIRILMASIALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., ÇİFTÇİLER R., SAYINALP N., et al.4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)
7. MULTİPLE MYELOM HASTALARINDA İNDUKSİYON TEDAVİ SÜRESİNİN SAĞKALIMA ETKİSİALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., et al.3. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Türkiye, 8 - 09 Mart 2019, (Özet Bildiri)
8. Alt Ekstremite Artropatisi Olan ve Olmayan Hemofilik Bireylerin Yaşam Kalitesi, Depresyon ve Anksiyete Seviyelerinin KarşılaştırılmasıAYKAR S., CAN F., AKSU S.28. Ulusal Türk Ortopedi ve Travmatoloji Kongresi, Türkiye, 30 Ekim - 04 Kasım 2018, (Özet Bildiri)
9. Long-Term Results of Non-Fludarabine Versus Fludarabine-Based Conditioning Regimens in Severe Aplastic Anemia PatientsALADAĞ KARAKULAK E., DEMİROĞLU H., Ciftciler R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., et al.60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)
10. LENALIDOMID İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİBE KIYASLA DAHA İYİ İLERLEMESİZ SAĞKALIMDEMİROĞLU H., AKSU S., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., et al.TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)
11. AĞIR APLASTİK ANEMİ HASTALARINDA HEMATOPOETİK KÖK HÜCRE NAKLİNDE KULLANILAN HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASIALADAĞ KARAKULAK E., DEMİROĞLU H., ÇİFTÇİLER R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., et al.44.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.261, (Özet Bildiri)
12. LENALİDOMİD İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİB’E KIYASLA DAHA İYİ İLERLEMESİZ SAĞKALIMMALKAN Ü. Y., BÜYÜKAŞIK Y., DEMİROĞLU H., ÇİFTÇİLER R., GÜNEŞ G., OKAY M., et al.44.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.191-192, (Özet Bildiri)
13. MRG’DE TESADÜFEN SAPTANAN KEMİK İLİĞİNİN DİFFÜZ SİNYAL DEĞİŞİKLİKLERİ LENFOHEMATOPOETİK HASTALIKLARI ÖNGÖREBİLİR Mİ?ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., et al.44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.266, (Özet Bildiri)
14. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphomaOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., CIFTCILER R., Aladag E., et al.9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Türkiye, 17 - 20 Ekim 2018, cilt.73, (Özet Bildiri)
15. Descriptive analysis of myeloproliferative diseases and its complicationsOKAY M., MALKAN Ü. Y., BÖLEK E. Ç., Aladag E., HAZIYEV T., SAYINALP N., et al.9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Türkiye, 17 - 20 Ekim 2018, cilt.73, (Özet Bildiri)
16. RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANNTRON-MELFALAN HAZIRLAMA REJİMİOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., malkan Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., et al.6. HEMATOLOJİK ONKOLOJİ KONGRESİ, Türkiye, 18 - 22 Eylül 2018, (Tam Metin Bildiri)
17. RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANTRON-MELFALAN HAZIRLAMA REJİMİOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., et al.5. HEMATOLOJİK ONKOLOJİ KONGRESİ, Kıbrıs (Kktc), 20 - 22 Eylül 2018, (Özet Bildiri)
18. AKUT MYELOİD LÖSEMİLİ BİR OLGULDA SİTOZİN ARABİNOZİD İLİŞKİLİ PULMONER TOKSİSİTEÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., AKSU S., DEMİROĞLU H., GÖKER H., et al.4.İLAÇ VE TEDAVİ KONGRESİ, Kıbrıs (Kktc), 19 - 23 Eylül 2018, ss.254, (Özet Bildiri)
19. EFFECT OF THE INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTSALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.The International Congress of BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, (Özet Bildiri)
20. PLAZMA HÜCRELİ LÖSEMİ ŞEKLİNDE PREZENTE OLAN WALDENSTROM MAKROGOBULİNEMİSİÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., HEZİYEV T., AKSU S., SAYINALP N., et al.2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Mayıs 2018, (Özet Bildiri)
21. KINESIOPHOBIA, QUALITY OF LIFE, DEPRESSION AND ANXIETY LEVEL IN ADULT HEMOPHILIAC PATIENTS: A CONTROLLED STUDYAYKAR S., CAN F., AKSU S.EAHAD 2018, 7 - 09 Şubat 2018, cilt.24, ss.32-135, (Özet Bildiri)
22. EFFECT OF INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTSDEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., et al.INTERNATIONAL CONGRESS OF BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, cilt.53, (Tam Metin Bildiri)
23. Amyloidosis Induced Abnormal coagulopathy associated with multible coagulation Factor Deficiencies.malkan Ü. Y., DEMİROĞLU H., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N.XXVI. Congress of the international society on Thrombosis and Haemostasis, Berlin, Almanya, 08 Temmuz 2017 - 13 Ocak 2018, cilt.1, ss.402, (Özet Bildiri)
24. Echocardiographic Evaluation of Patients with Hodgkin and Non Hodgkin Lymphoma before and after Hematopoietic Stem Cell TransplantationKELKİTLİ E., BÜYÜKAŞIK Y., DEMİROĞLU H., ŞAHİNER M. L., OKAY M., AYDIN M. S., et al.59th ASH, 9 - 12 Aralık 2017, cilt.130, ss.5521, (Özet Bildiri)
25. Prognosis of Multiple Myeloma in Younger Patients Who Are Undergoing Upfront Autologuous Stem Cell TransplantationKELKİTLİ E., GÖKER H., DEMİROĞLU H., TURGUT M., OKAY M., SAYINALP N., et al.LYMPHOMA AND MYELOMA 2017, New York, Amerika Birleşik Devletleri, 26 - 28 Kasım 2017, cilt.1, ss.43-44, (Özet Bildiri)
26. Donor Lymphocyte Infusions: Single Center ExperienceKELKİTLİ E., GÖKER H., TURGUT M., DEMİROĞLU H., SAYINALP N., AKSU S., et al.LYMPHOMAMYELOMA 2017, New York, Amerika Birleşik Devletleri, 26 - 28 Kasım 2017, cilt.1, ss.48, (Özet Bildiri)
27. Donor Lymhocyte Infusion: Single Center ExperienceKELKİTLİ E., GÖKER H., TURGUT M., Demiroğlu H., SAYINALP N., AKSU S., et al.LYMHOMA MYELOMA 2017, 26 - 28 Ekim 2017, (Özet Bildiri)
28. Prognosis of Multiple Myeloma in Younger Patients who Undergoing Upfront Autologous Stem Cell TransplantationKELKİTLİ E., GÖKER H., demiroglu H., TURGUT M., SAYINALP N., AKSU S., et al.LYMPHOMA MYELOMA 2017, 26 - 28 Ekim 2017, (Özet Bildiri)
29. Ayak Bileği Burkulması Olan Bir Hemofili Hastasında Kuvvetlendirme Egzersizleri, Manuel Tedavi ve Proprioseptif Eğitimin Ağrı, Ayak Fonksiyonları ve Hareket Korkusuna Olan Etkisi.ÖNAL S., CAN F., AKSU S.14. Türkiye Hemofili Kongresi, Türkiye, 12 - 15 Nisan 2017, (Özet Bildiri)
30. BLEOMYCIN-INDUCED INTERSTITIAL LUNG DISEASE: A CASE REPORTMalkan Ü. Y., GÜNEŞ G., Aslan T., AKSU S., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
31. AN ACUTE MYELOID LEUKEMIA PATIENT COMPLICATED WITH HYPERLEUKOCYTOSISMalkan Ü. Y., GÜNEŞ G., Yayar O., HAZNEDAROĞLU İ. C., AKSU S., ÖZCEBE O. İ.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
32. TREATMENT OF PYODERMA GANGRENOSUM WITH THALIDOMIDE IN MYELODYSPLASTIC SYNDROME: A CASE REPORTMalkan Ü. Y., GÜNEŞ G., Yayar O., Aslan T., AKSU S., HAZNEDAROĞLU İ. C.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
33. A PLASMA CELL LEUKEMIA CASEMalkan Ü. Y., GÜNEŞ G., ETGÜL S., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
34. THERAPY-RELATED MYELODYSPLASTIC SYNDROME AFTER THE SUCCESSFUL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIAMalkan Ü. Y., GÜNEŞ G., Yayar O., AKSU S., DEMİROĞLU H., HAZNEDAROĞLU İ. C.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
35. A LATE-ONSET ACUTE GRAFT VERSUS HOST DISEASE CASE WHO IS RESISTANT TO BOTH TACROLIMUS AND CYCLOSPORINEMalkan Ü. Y., GÜNEŞ G., Aslan T., AKSU S., GÖKER H., HAZNEDAROĞLU İ. C.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
36. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CMLAKSU S., Aktimur S. H., Arica D. C., Atay H., Bektas O., BÜYÜKAŞIK Y., et al.20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.690, (Özet Bildiri)
37. Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factorsGoker H., Gunes G., Demiroglu H., Malkan Ü. Y., Haznedaroglu I., Sayinalp N., et al.Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
38. Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoetic Stem Cells) When Compared to Standard AdministrationGÖKER H., ELİAÇIK E., Altuntas F., Tekgunduz E., ÖZDEMİR E., Isik A., et al.56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri)
39. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CMLAKSU S., AKTİMUR S., ARİCA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., et al.20th Congress of the European Hematology Association Vienna, Austria June 11-14, 2015, 11 - 14 Haziran 2014, (Tam Metin Bildiri)
40. Impacts on Functional Outcomes Following Total Knee Arthroplasty in Hemophilia Patients: A Comparative Study of Pain Catastrophizing and Adaptation to Artificial JointsKANLIKAYA U. G., KINIKLI G. İ., GÖKER B., ATİLLA B., ÇAĞLAR Ö., TOKGÖZOĞLU A. M., et al.
41. Pain Catastrophizing, Kinesiophobia, Adaptation To Artificial Joint And Functional Outcomes Following Total Knee Arthroplasty In Hemophilia: A Matched Cohort StudyKANLIKAYA U. G., GÖKER B., KINIKLI G. İ., ATİLLA B., TOKGÖZOĞLU A. M., ÇAĞLAR Ö., et al.
42. AbstractsBOZGEYİK S., KINIKLI G. İ., AKSU S., ATİLLA B., GÜNEY DENİZ H.
43. DASATİNİB KULLANIRKEN PLEVRAL EFFÜZYONU GELİŞİP, KÜÇÜK HÜCRELİ AKCİĞER KANSERİ TANISI ALAN BİR OLGUÇİFTÇİLER R., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., AKSU S., et al.
44. The Impact of Chemo/Immune Therapy-­‐Related Cytopeniason the Clinical Course of Chronic Lymphoid LeukemiaOKAY M., HAZNEDAROĞLU İ. C., malkan Ü. Y., GÜNEŞ G., aslan n., AKSU S., et al.
45. Serological response to influenza vaccine haematopoetic stem cell transplantation patientsYALÇIN Ş., Kondolot M., Albayrak N., Altas B., Karacan Y., KUŞKONMAZ B. B., et al.